Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

Intellia Therapeutics (NTLA) Return on Capital Employed (2016 - 2026)

Intellia Therapeutics has reported Return on Capital Employed over the past 11 years, most recently at 58.11% for Q1 2026.

  • Quarterly Return on Capital Employed fell 267.0% to 58.11% in Q1 2026 from the year-ago period, while the trailing twelve-month figure was 58.11% through Mar 2026, down 267.0% year-over-year, with the annual reading at 48.32% for FY2025, 125.0% down from the prior year.
  • Return on Capital Employed was 58.11% for Q1 2026 at Intellia Therapeutics, down from 56.55% in the prior quarter.
  • Over five years, Return on Capital Employed peaked at 31.19% in Q1 2023 and troughed at 60.45% in Q2 2025.
  • The 5-year median for Return on Capital Employed is 44.54% (2023), against an average of 46.25%.
  • Year-over-year, Return on Capital Employed crashed -1898bps in 2022 and then soared 359bps in 2023.
  • A 5-year view of Return on Capital Employed shows it stood at 38.97% in 2022, then fell by -14bps to 44.54% in 2023, then fell by -12bps to 49.87% in 2024, then fell by -13bps to 56.55% in 2025, then fell by -3bps to 58.11% in 2026.
  • Per Business Quant, the three most recent readings for NTLA's Return on Capital Employed are 58.11% (Q1 2026), 56.55% (Q4 2025), and 58.5% (Q3 2025).